Impact of Pharmacogenomics on Public Healthcare Policy
During the last fifteen years tremendous advances have been made in deciphering the genetic coding of a variety of species from invertebrates, vertebrates and finally man through the formal initiation of the Human Genome Project in October 2000 and its completion in 2003. This information has helped to increase our understanding of how genetics has a pivotal role in the predisposition of many diseased states, the progression of a course of a disease, as well as a patient’s response to a drug, or lack of it. Now in the 21st Century there is a growing trend towards the development of personalized medicine – the right drug for the right individual.
Examine the rapidly advancing fields of pharmacogenomics and pharmacogenetics, and measure the impact of pharmacogenomic techniques on reimbursement and health economics with this new report.
More Research Reports
- Pricing and Reimbursement in Key Asia Pacific Markets
- Delivery Mechanisms for Large Molecule Drugs: Successes and failures of leading technologies and key drivers for market success
- The Cardiovascular Market Outlook to 2013: Competitive landscape, global market analysis and pipeline analysis
- Intellectual Property and Outsourcing in China: Minimizing risk whilst maximizing return on investment
- Health Care Equipment & Supplies: Global Industry Guide
- 2009 Trends to Watch: Healthcare Technology
- The Cancer Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Gastrointestinal, Skin, Sarcomas
- Forecast Insight: Depression - Generic induced brand erosion leads to market decline
- Stakeholder Opinions: Type 2 Diabetes in the UAE & Saudi Arabia Growth opportunities in fragmented markets





